Table. The risks of perimenopausal hormone therapy^*1.

Endpoint	Absolute risk
Thrombo-embolic events	ET: +6 events/10000 women/year (21 [HT] vs. 15 events [placebo])
	EPT: +18 events/10000 women/year (35 [HT] vs. 17 events [placebo])
Any biliary disease	ET: +31 events/10000 women/year (78 [HT] vs. 47 events [placebo])
	EPT: +20 events/10000 women/year (55 [HT] vs. 35 events [placebo])
Breast cancer	ET: −7 events/10000 women/year (26 [HT] vs. 33 events [placebo]) (ns)
	EPT: +8 events/10000 women/year(38 [HT] vs. 30 events [placebo])
Stroke	ET (any stroke): +12 events/10000 women/year (44 [HT] vs. 32 events [placebo])
	EPT (ischemic stroke): +8 events/10000 women/year (26 [HT] vs. 18 events [placebo])

^*1Published data from the available studies in which absolute risk figures are given for the four endpoints in the left column of the table. These risks may be independent of the duration of therapy and the time of its initiation in relation to the age of menopause (see text; adapted from [2]).HT, hormone therapy; ET, estrogen therapy; EPT, estrogen-gestagen therapy: ns, not significant.